The tumor-associated CD4+ T cell clones in STIE peripheral blood have higher cytotoxic activity than the CD8+ T cell clones, but post-progressive CD8+ T cells can be observed in patients with disease progression. The gene discussed is CD4; the disease is neoplasm.